Novartis AG Reports Positive Topline Phase 2 Data
Novartis AG (NYSE: NVS) today reported positive topline data from its Phase 2 study for ensovibep. Viral Load Reduction The Part A of the EMPATHY clinical trial met the primary endpoint of viral load reduction over eight days, while the...